2Humar A , Mazzulli T, Moussa G , et al. Clinical utility of cytomegalovirus (CMV)serology testing in high-risk CMV D+/R- transplant recipients[J]. Am J Transplant, 2005,5(5):1065-1070.
3Piiparinen H , Helantera I , Lappalainen M, et al. Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients[J]. J Med Virol, 2005,76 ( 3 ) :367-372.
4Morales E , Andres A , Gonzalez E , et al. Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy[J] . Transplant Proc,2002,34( 1 ) :73-74.
5Pass RF, Burke RL. Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection[J] .Semin Pediatr Infect Dis , 2002 , 13 ( 3 ) : 196-204.
6Berencsi K , Gyulai Z , Gonczol E , et al. A canarypox vector-expressing cytomegalovirus ( VMV ) phosphoprotein 65 induces long lasting cytotoxic T cell responses in human CMV-seronegative subjects[J]. J Infect Dis,2001,183 ( 8 ) :1171-1179.
7Gonczol E. Cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients [J]Anon Drug Fut, 1999,24 ( 7 ) :829-831.
8Wiltshire H , Hirankarn S , Farrell C , et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients [J].Clin Pharmacokinet ,2005 ,44 ( 5 ) :495-507.
9Kalpoe JS , Schippers EF , Eling Y , et al. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation[J] . Antivir Ther , 2005 , 10(1) :119-123.
10Fellay J, Venetz JP, Aubert JD , et al. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir[J]. Transplant Proc , 2005 , 37 ( 2 ) :949-951.